5AM Ventures

We are excited to announce two poster presentations for DNTH103 at the 10th Congress of the European Academy of Neurology (EAN) in Helsinki.   June 29, 2024, 14:10 EEST DNTH103, Investigational Therapy for Generalised Myasthenia Gravis Session: Muscle and Neuromuscular Junction Disorder 1; Presentation Number: EPR-118 June 30, 2024, 14:25 EEST DNTH103: Preventing Nerve Damage in a CIDP Model via Sustained Complement Inhibition Session: Muscle and Neuromuscular Junction Disorder 2; Presentation Number: EPR-243 These posters will be made available after they are presented on the Dianthus website: https://lnkd.in/gZz2x_tw DNTH103 is an investigational agent that is not approved as a therapy in any indication in any jurisdiction worldwide. #ean2024 #neurology

Radionetics Oncology enters into strategic agreement with Lilly. Learn more about us at www.radionetics.com

Entrada Therapeutics announces $100 million registered direct offering. The offering was led by a U.S.-based healthcare focused investor, two global mutual funds and Janus Henderson Investors, a global asset management firm. Learn more here: https://lnkd.in/dDZpdq4d

Entrada Therapeutics reports preliminary data in healthy volunteers from Phase 1 ENTR-601-44-101 trial for Duchenne muscular dystrophy. Learn more here: https://lnkd.in/dMPZtt9a

We are excited to announce we received FDA clearance of our Phase 2 Investigational New Drug (IND) application for the MoMeNtum trial of DNTH103 in patients with Multifocal Motor Neuropathy (MMN). Top-line results are expected to be available in the second half of 2026. Learn more: https://lnkd.in/ggZZeSfZ #biotech #MMN

Today we reached another exciting clinical milestone in our journey to deliver a paradigm shift in the treatment of chronic inflammatory diseases, announcing positive data from a Phase Ib/IIa #cardiovascular risk study of our lead brain-penetrant #NLRP3 #inflammasone inhibitor candidate, NT-0796. The trial met its primary endpoint, demonstrating a highly statistically significant and rapid reduction of C-reactive protein (CRP), a key biomarker of chronic #cardiometabolic inflammatory diseases, in inflamed obese subjects dosed with NT-0796 compared to placebo. The study also saw reductions in body weight, the most pronounced among high-risk subgroups, supporting the anti-obesity potential of the molecule. Preparations are now underway for a Phase II #obesity study alongside other Phase IIa studies in additional cardiometabolic diseases and #ParkinsonsDisease. Learn more: https://bit.ly/4aYdBPR #NeuroInflammation #DrugDiscovery #Biotech

We are pleased to welcome Daniel Swisher as Chief Executive Officer! Dan joins the team with more than 30 years of leadership expertise in the #LifeSciences industry. During his career, he has led the advancement and commercialization of novel therapeutics in multiple therapeutic areas, including #neuroscience and #RareDiseases, and has significant experience in driving cross function, high-performing teams and relationship building. NodThera’s founder and interim CEO, Alan Watt, becomes our President and CSO, responsible for growing the Company’s R&D organisation and strengthening our world-leading position in #NLRP3 #inflammasome research. Find out more here: https://lnkd.in/d4vYKka7 #Appointment #NewHire #NeuroInflammation #WelcomeToTheTeam

We’re thrilled to announce that the #KariusTest has been granted designation as a Breakthrough Device from the FDA for use in the diagnosis and management of immunocompromised patients with suspected lung infections, including lower respiratory infection and pneumonia. “The Karius Test is commercially available nationwide as a laboratory developed test. We are seeking FDA marketing authorization of the Karius Test for lung infections in immunocompromised patients because improved diagnostic tests are urgently needed for these patients,” said Brad Perkins, our Chief Medical Officer. As noted in the American Thoracic Society Workshop Report for Immunocompromised Host Pneumonia: Definitions and Diagnostic Criteria, lung infections have high morbidity and mortality in immunocompromised patients, which is why advances in technologies like metagenomic sequencing used for the Karius Test are vital in improving the diagnosis and treatment of these patients.” New data on the Karius Test and cost-effectiveness in pneumonia will be presented at #ATS2024. https://hubs.li/Q02xnTnm0 #FDA #pneumonia #infectiousdiseases #metagenomic #breakthroughdevice

We are excited to welcome Dr. Neil Gallagher MD PhD, as Chair of our R&D Committee and Independent Advisor to our Board.   With 20+ years in global pharma and biotech, and notable leadership in oncology drug development and registration, Dr. Gallagher brings invaluable expertise, enabling our mission of generating safe, innovative cancer #immunotherapies.   To find out more visit our website: https://www.nouscom.com/   #Innovation #Cancervaccine #Nouscom #Cancerinterception #Patients  

Today, we are thrilled to announce the appointment of accomplished biotechnology executive, Jim Burns, Ph.D., as chief executive officer. Dr. Burns joins Ensoma at a critical and exciting time for the company as we advance our first program through IND-enabling studies. We are pleased to add his expertise, experience and previous leadership in gene and cell therapies to our team. Learn more below. https://lnkd.in/g3HTNuzK